- Home
- AUST vs MBRX Comparison
AUST vs MBRX Comparison
Compare AUST & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | MBRX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 23.5M |
| IPO Year | 2022 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AUST | MBRX |
|---|---|---|
| Price | $1.78 | $4.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $105.50 |
| AVG Volume (30 Days) | 98.0K | ★ 300.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $4.75 |
| 52 Week High | $2.94 | $91.25 |
Technical Indicators
Market Signals| Indicator | AUST | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 58.02 |
| Support Level | $1.75 | $4.75 |
| Resistance Level | $2.15 | $7.98 |
| Average True Range (ATR) | 0.17 | 0.65 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 39.45 | 55.56 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.